|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2009-12-2
|
|
pubmed:abstractText |
CH4987655 (RO4987655) is an orally active and highly selective small-molecule MEK inhibitor. It potently inhibits mitogen-activated protein kinase signaling pathway activation and tumor cell growth, with an in vitro IC(50) of 5.2 nmol/L for inhibition of MEK1/2. Single-agent oral administration of CH4987655 resulted in complete tumor regressions in xenograft models.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BarrettJoanneJ,
pubmed-author:Busse-ReidRachelR,
pubmed-author:De SchepperStefanieS,
pubmed-author:DeutschJonathanJ,
pubmed-author:GimmiClaudeC,
pubmed-author:GoelzerPetraP,
pubmed-author:IgawaYurikoY,
pubmed-author:IshiiNobuyaN,
pubmed-author:IshikawaYujiY,
pubmed-author:LeeLucyL,
pubmed-author:MuSongS,
pubmed-author:NiuHuifengH,
pubmed-author:PeckRichardR,
pubmed-author:RuegerRuedigerR,
pubmed-author:SakamotoYuuichiroY,
pubmed-author:WeissgerberGeorgesG,
pubmed-author:YoshimuraYashushiY
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7368-74
|
|
pubmed:meshHeading |
pubmed-meshheading:19934286-Administration, Oral,
pubmed-meshheading:19934286-Adolescent,
pubmed-meshheading:19934286-Adult,
pubmed-meshheading:19934286-Antineoplastic Agents,
pubmed-meshheading:19934286-Area Under Curve,
pubmed-meshheading:19934286-Biological Markers,
pubmed-meshheading:19934286-Dose-Response Relationship, Drug,
pubmed-meshheading:19934286-Double-Blind Method,
pubmed-meshheading:19934286-Enzyme Inhibitors,
pubmed-meshheading:19934286-Female,
pubmed-meshheading:19934286-Humans,
pubmed-meshheading:19934286-Inhibitory Concentration 50,
pubmed-meshheading:19934286-MAP Kinase Signaling System,
pubmed-meshheading:19934286-Male,
pubmed-meshheading:19934286-Middle Aged,
pubmed-meshheading:19934286-Neoplasm Transplantation,
pubmed-meshheading:19934286-Placebos,
pubmed-meshheading:19934286-Tumor Markers, Biological
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.
|
|
pubmed:affiliation |
Clinical Pharmacology, Hoffman-La Roche, Nutley, New Jersey 07110, USA. lucy.lee@roche.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
